Figures & data
Figure 1. A (baseline): clinical aspect and dermoscopy (insert) of AA universalis; B (three months): regrowth (circles) under baricitinib treatment (4 mg/day); C (five months): relapse within the regrowth areas (circles) while under baricitinib (Phenotype 1); localized new areas of regrowth were observed (arrows).
![Figure 1. A (baseline): clinical aspect and dermoscopy (insert) of AA universalis; B (three months): regrowth (circles) under baricitinib treatment (4 mg/day); C (five months): relapse within the regrowth areas (circles) while under baricitinib (Phenotype 1); localized new areas of regrowth were observed (arrows).](/cms/asset/435d486f-dfd2-42e0-8b35-3b68f2c60782/ijdt_a_2324832_f0001_c.jpg)